1. Bossi, P., Viale, G., Lee, A. K. C., Alfano, R. M., Coggi, G. & Bosari, S. (1995). Angiogenesis in colorectal tumors: microvessel quantitation in adenomas and carcinomas with clinicopathological correlations. Cancer Res 55: 5049–5053.
2. Chiu, C., McEntee, M. F. & Whelan, J. (1997). Sulindac causes rapid regression of preexisting tumors in Min/+ mice, independent of prostaglandin biosynthesis. Cancer Res 57: 4267–4273.
3. D’Amato, R. J., Loughnan, M. S., Flynn, E. & Folkman, J. (1994). Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082–4085.
4. Duggan, D. E., Hooke, K. F., Risley, E. A., Shen, T. Y. & Van Arman, C. G. (1977). Identification of the biologically active form of sulindac. J Pharm Exp Ther 201: 8–13.
5. Fine, H. A. (1997). A phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas (abstract). In Thalidomide: Potential Benefits and Risks, Open Public Scientific Workshop, p. 85. National Institute of Health: Bethesda MD